As CTX is increasingly gaining recognition as an inborn error of metabolism, newborn screenings are currently being researched to assess their accuracy in identifying patients with CTX.

It is imperative to improve clinical suspicion among healthcare providers to intervene before the debilitating neurologic and non-neurologic sequela of the disease emerge. A suspicion index has already been created to help providers order the appropriate tests when patients and families note symptoms.